The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.

被引：0
|
作者：
Kong, SY [1 ]
Kwon, Y [1 ]
Lee, DH [1 ]
Lee, JS [1 ]
Lee, ES [1 ]
Ro, J [1 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48S / 48S
页数：1
相关论文
共 50 条
  • [21] HER2 Testing for Breast Cancer in the Genomics Laboratory A Sea Change for Fluorescence In Situ Hybridization
    Geiersbach, Katherine B.
    Sill, Daniel R.
    Meyer, Reid G.
    Yuhas, Jason A.
    Sukov, William R.
    Mounajjed, Taofic
    Carter, Jodi M.
    Jenkins, Robert B.
    Chen, Beiyun
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (07) : 883 - 886
  • [22] Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer
    Kammori, Makoto
    Kurabayashi, Rie
    Kashi, Mitsuhiko
    Sakamoto, Akiko
    Yoshimoto, Masataka
    Amano, Sadao
    Kaminishi, Michio
    Yamada, Tetsu
    Takubo, Kaiyo
    ONCOLOGY REPORTS, 2008, 19 (03) : 651 - 656
  • [23] Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer
    Furrer, Daniela
    Jacob, Simon
    Caron, Chantal
    Sanschagrin, Francois
    Provencher, Louise
    Diorio, Caroline
    ANTICANCER RESEARCH, 2017, 37 (06) : 3323 - 3329
  • [24] Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer
    Astvatsaturyan, K.
    Bose, S.
    MODERN PATHOLOGY, 2013, 26 : 28A - 28A
  • [25] Disparities in HER2 testing in breast cancer.
    Paryani, Vijay
    Schroeder, Mary Chen
    Klepin, Heidi D.
    Melin, Susan Anitra
    Russell, Greg B.
    Winkfield, Karen Marie
    Thomas, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Dual-Color In Situ Hybridization (Dual ISH) for Evaluation of HER2/Neu (HER2) Amplification in Breast Cancer
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2013, 93 : 28A - 28A
  • [27] HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX
    Tozbikian, Gary H.
    Zynger, Debra L.
    BREAST JOURNAL, 2018, 24 (04): : 535 - 540
  • [28] Assessment of HER2 status in breast cancer by fluorescence in situ hybridisation
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 235 - 236
  • [29] The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer
    Xu, Zhigao
    Xu, Peipei
    Fan, Wei
    Huang, Ben
    Cheng, Qingyuan
    Zhang, Zheng
    Wang, Ping
    Yu, Mingxia
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (03) : 2095 - 2103
  • [30] HER2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization
    Shirsat, Hemlata S.
    Epari, Sridhar
    Shet, Tanuja
    Bagal, Rajani
    Hawaldar, Rohini
    Desai, Sangeeta B.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2012, 55 (02) : 175 - 179
12345